22,586 Shares in Upstream Bio, Inc. $UPB Bought by Nuveen LLC

Key Points

• Nuveen LLC acquired 22,586 shares of Upstream Bio during the 1st quarter, valued at approximately $138,000, marking a significant investment in the company.
• Analysts upgraded Upstream Bio from a "sell" to a "hold" rating, with four analysts giving the stock a "buy" rating and an average price target of $56.50.
• Upstream Bio reported a quarterly loss of ($0.74) EPS, missing estimates but achieving revenue of $0.94 million, exceeding expectations of $0.32 million.

Nuveen LLC bought a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 22,586 shares of the company's stock, valued at approximately $138,000.

A number of other hedge funds have also added to or reduced their stakes in UPB. BNP Paribas Financial Markets purchased a new stake in shares of Upstream Bio in the 4th quarter worth about $25,000. New York State Common Retirement Fund bought a new position in Upstream Bio in the 1st quarter worth about $29,000. Tower Research Capital LLC TRC bought a new position in Upstream Bio in the 4th quarter worth about $47,000. XTX Topco Ltd bought a new position in Upstream Bio during the 1st quarter valued at about $78,000. Finally, Wells Fargo & Company MN bought a new position in Upstream Bio during the 4th quarter valued at about $149,000.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Upstream Bio from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $56.50.

Upstream Bio Stock Up 1.5%

Shares of UPB opened at $19.97 on Friday. The stock has a 50 day moving average price of $14.80 and a 200 day moving average price of $10.90. Upstream Bio, Inc. has a 52-week low of $5.14 and a 52-week high of $29.46.

Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.13). The business had revenue of $0.94 million during the quarter, compared to analyst estimates of $0.32 million. Upstream Bio had a negative net margin of 3,836.58% and a negative return on equity of 35.90%. Research analysts anticipate that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

Want to see what other hedge funds are holding UPB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Upstream Bio, Inc. (NASDAQ:UPB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.